Psychiatr. pro Praxi, 2003; 1: 23-28

Dystymie a její léčba - 2. díl

doc. MUDr. Ján Praško CSc1,3,2,4, MUDr. Erik Herman5,7,6, doc. MUDr. Jiří Hovorka CSc6,8
1 Psychiatrické centrum Praha, 3. LF UK, Praha
2 Centrum neuropsychiatrických studií, Praha
3 Psychiatrická klinika FN a LF UP, Olomouc
4 3. LF UK, Praha
5 Psychiatrická klinika 1. LF UK a VFN Praha
6 Neurologické oddělení, neuropsychiatrické a epileptologické centrum, Nemocnice Na Františku s poliklinikou, Praha
7 Psychiatrická ambulance, Praha
8 Neurochirurgická klinika 1. LF UK, Praha

Keywords: pharmacotherapy, psychotherapy, interpersonal therapy, cognitive behavioral therapy.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praško J, Herman E, Hovorka J. Dystymie a její léčba - 2. díl. Psychiatr. praxi. 2003;4(1):23-28.

První výzkumné diskuze o použití psychoterapie u dystymie se datují do roku 1984, kdy chronické deprese byly reklasifikovány mezi poruchy nálady a byl ověřen efekt antidepresiv. Několik psychoterapeutických studií věnovaných dystymii však zatím trpí metodologickou nedostatečností, malými studijními vzorky nebo obojím. Několik kognitivně-behaviorálních přístupů bylo testováno u této populace. Tyto přístupy měly odlišnou účinnost (33-67% responderů) po 2-3měsíční době léčby. Také interpersonální psychoterapie (IPT) ukázala u dystymie účinnost ve třech malých pilotních pracech. Efektivnita IPT byla podobná jako u medikace.

DYSTHYMIA AND ITS THERAPY

The first research discussion of psychotherapy of dysthymic disorder dates back to 1984, when chronic depression had recently been reclassified as a mood disorder and researchers were exploring benefits of antidepressant medication for its treatment. The few psychotherapy studies of dysthymic disorder generally suffer from methodological weakness, small sample size, or both. Several cognitive-behavior therapy approaches have been tested for treating dysthymic patients. These approaches have different response rate (33-67% responders) after 2-3 months trials. Interpersonal psychotherapy, has demonstrated efficacy in three small pilot studies with dysthymic patients. IPT response was equivalent to medication.

<sup>1</sup>Psychiatrické centrum Praha, III. LF UK Centrum neuropsychiatrických studií <sup>2</sup>Psychiatrická ambulance Praha, I. LF UK <sup>3</sup>Neurologické oddělení a neuropsychiatrické centrum, Nemocnice Na Františku, Praha

II. neurochirurgická klinika 1. LF UK a ÚVN, Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akiskal HS. Dysthymia: clinical and external validity. Acta Psychiatr Scand 1994; 383: 19-23. Go to original source... Go to PubMed...
    2. Akiskal HS. Dysthymia, cyclothymia, and related chronic subtreshold mood disorders. In: Geodet MG, López - Ibor, JJ a Andreasen NC: New Oxford Textbook of Psychiatry, Oxford University Press 2000; 736-749.
    3. Akiskal HS. Subaffective disorders: dysthymic, cyclothymic, and bipolar II disorders in the, ,borderline" realm. Psychiatr Clin North Am 1981; 4: 25-46. Go to original source... Go to PubMed...
    4. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am. J. Psychiatry 1983; 140: 11-20. Go to original source... Go to PubMed...
    5. Amore M, Jori MC. Faster response on amisulprid 50 mg versus sertraline 50-100 mg in patiens with dysthymia or double depression: a randomized, double-blind, paralel group study. Int Clin Psychopharmacology 2001; 16: 317-324. Go to original source... Go to PubMed...
    6. Arias F, Padin JJ, Gilberte I, Sanches R, Gomez S, Garcia D. Komparative efficacy and tolerability aminy different selective serotoninu re-uptake inhibitors and venlafaxine in a naturalistic setting. Int J Psychiatry Clin Prac 1998; 2: 255-260. Go to original source... Go to PubMed...
    7. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999; 39: 25-32. Go to original source... Go to PubMed...
    8. Dunner DL, Schmaling KB, Hendrickson H, Becker J, Lehman A, Bea C. Cognitive therapy versus fluoxetin in the treatment of dysthymic disorder. Depression 1996; 4: 34-41. Go to original source... Go to PubMed...
    9. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997; 58: 528-531. Go to original source... Go to PubMed...
    10. Feijo-de-Mello M, Myczowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychotherapy Pract Res 2001; 10: 117-123.
    11. Gonzales LR, Lewinsohn PM, Clarke GN. Longitudinal follow up of unipolar depressives: an investigation of predictors of relaps. J Konsult Clin Psychol 1985; 53: 461-469. Go to original source...
    12. Harpin RE, Liberman RP, Marks I. Cognitive-behavior therapy for chronically depressed patiens: a controlled pilot study. J Nerv Ment Dis 1982; 170: 56-62. Go to original source... Go to PubMed...
    13. Hellerstein DJ, Samstag LW, Little S, Xanowitch P. Dysthymia. Assessing symptoms and treatment response with the Cornell Dysthymia Rating Scale. Presented at the Annual meeting, American Psychiatric Assn., Philadelphia, May 21-26 (New research program and abstrakt p 111) 1994.
    14. de Jorg R, Treiber R, Hendrich G. Effectiveness of two psychological treatments for inpatiens with severe and chronic depression. Cognitive Ther and Res 1986: 10: 645-663. Go to original source...
    15. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride study group: amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disorde 1997; 43: 95-103. Go to original source... Go to PubMed...
    16. Lee HS, Kim SH, Suh KY, Klak DI. Efficacy of sertraline in dysthymia. Presented at the XIXth CINP Congress, Washington DC, June 27 - July 1. Neuropsychopharmacology 10 (No 3S/Part 2) 1994; 222S.
    17. Malá E. Trvalé poruchy nálady. In: Hort V, Hrdlička M, Koucourková J, Malá, E. (ed.). Dětská a adolescentní psychiatrie. Portál, Praha 2000: 210-214.
    18. Markowitz JC. Interpersonal psychotherapy for dysthymic disorder. American Psychiatry Press, Inc. 1996, Philadelphia 1996; 184 s.
    19. Markowitz JC. Psychotherapy of dysthymia. Am J Psychiatry 1994; 151: 1114-1121. Go to original source... Go to PubMed...
    20. Markowitz JC, Klerman GL, Perry S. Interpersonal psychotherapy of depressed HIV-seropositive outpatients. Hosp. Community Psychiatry 1992; 43: 885-890. Go to original source... Go to PubMed...
    21. Mason BJ, Markowitz J, Klerman GL. IPT for dysthymic disorder, In: Klerman GL, Weissman MM (eds). New Applications of Interpersonal Therapy. American Psychiatric Press, Washington DC. 1993; 225-264.
    22. McCullough JP. Psychotherapy for dysthymia: a naturalistic study of ten patients. J Nerv Ment Dis 1991; 179: 734-740. Go to original source... Go to PubMed...
    23. Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování: Popisy klinických příznaků a diagnostická vodítka. (přeloženo z anglického originálu) Praha, Psychiatrické centrum 1992, Zprávy č. 102, 282 s.
    24. Možný P, Praško J. Kognitivně behaviorální terapie: úvod do teorie a praxe. Triton, Praha 1999: 304 s.
    25. Nobler MS, Devanand DP, Winter (tm), Roose SP, Sackheim HA. Fluoxetine treatment for elderly patiens with dysthymic disorder: a pilot study. Presented at the Annual meeting, American Psychiatric Assn., Philadelphia, May 21-26 (New research program and abstrakt p 91) 1994.
    26. Pani L, Gessa GL. The role of dopamine in the biological basis of dysthymia. Italian J Psychiatry Behav Sci. 1998; 8: 5-9.
    27. Praško J, Kosová J. Kognitivně-behaviorální terapie úzkostných stavů a depresí. Triton, Praha 1998; 234 s.
    28. Praško J, Šlepecký M. Kognitivně-behaviorální terapie depresivních poruch. Psychiatrické centrum, Praha 1995; 181 s.
    29. Ravindran AV, Bialik RJ, Lapierre YD. Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry 1994; 39: 21-26. Go to original source... Go to PubMed...
    30. Ravizza L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. J Psychopharmacol 1999; 13: 248-254. Go to original source... Go to PubMed...
    31. Rosenthal J, Hemlock C, Hellerstein D, Yanowitch P, Kasch K, Schupak C, Samstag L, Winston A. A preliminary study of serotonergic antidepressants in treatment of dysthymia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 933-941. Go to original source... Go to PubMed...
    32. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double blind, comparative study. J Affective Dis. 1998; 48: 47-56. Go to original source... Go to PubMed...
    33. Stravynski A, Shanar A, Verreault R. A pilot study of the cognitive treatment of dysthymic disorder: Behavioural Psychotherapy 1991; 4: 369-372.
    34. Švestka J. Amisulprid - atypický preparát ve skupině antipsychotik 2. generace. Psychiatrie. 2000; 4: 191-200.
    35. Versiani M. Pharmacotherapy of dysthymia: a controlled study of imipramine, moclobemide or placebo. Neuropsychopharmacology 1994; 10: 298.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.